Recent cancer incidence trends in an observational clinical cohort of HIV-infected patients in the US, 2000 to 2011

Infectious Agents and Cancer

Dirk P Dittmer²  Sonia Napravnik³  Blossom Damania¹  Joseph J Eron³  Kristen Tamburro²  Elizabeth L Yanik⁴ 

[1] Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, 31–353 Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA;Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, 715 Mary Ellen Jones Building, Chapel Hill, NC, USA;Division of Infectious Diseases, University of North Carolina at Chapel Hill, 130 Mason Farm Rd, Chapel Hill, NC, USA;Department of Epidemiology, University of North Carolina at Chapel Hill, 130 Mason Farm Rd, Chapel Hill, NC, USA

关键词: Cancer;    AIDS-associated malignancies;    HIV;    AIDS;    Kaposi sarcoma;   

Others  :  803059
DOI  :  10.1186/1750-9378-8-18

 received in 2013-03-11, accepted in 2013-05-15,  发布年份 2013

【 摘 要 】

Background

In HIV-infected populations in developed countries, the most recent published cancer incidence trend analyses are only updated through 2008. We assessed changes in the distribution of cancer types and incidence trends among HIV-infected patients in North Carolina up until 2011.

Methods

We linked the University of North Carolina Center for AIDS Research HIV Clinical Cohort, an observational clinical cohort of 3141 HIV-infected patients, with the North Carolina Cancer registry. Cancer incidence rates were estimated across calendar years from 2000 to 2011. The distribution of cancer types was described. Incidence trends were assessed with linear regression.

Results

Across 15,022 person-years of follow-up, 202 cancers were identified (incidence rate per 100,000 person-years [IR]: 1345; 95% confidence interval [CI]: 1166, 1544). The majority of cancers were virus-related (61%), including Kaposi sarcoma (N = 32) (IR: 213; 95%CI: 146, 301), non-Hodgkin lymphoma (N = 34) (IR: 226; 95%CI: 157, 316), and anal cancer (N = 16) (IR: 107; 95%CI: 61, 173). Non-Hodgkin lymphoma was observed to decrease from 2000 to 2011 (decline of 15 cases per 100,000 person-years per calendar year, 95%CI: -27, -3). No other changes in incidence or changes in incidence trends were observed for other cancers (all P > 0.20).

Conclusions

We observed a substantial burden of a variety of cancers in this population in the last decade. Kaposi sarcoma and non-Hodgkin lymphoma were consistently two of the greatest contributors to cancer burden across calendar time. Cancer rates appeared stable across calendar years, except for non-Hodgkin lymphoma, which appeared to decrease throughout the study period.

【 授权许可】

   
2013 Yanik et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Hymes KB, Cheung T, Greene JB, Prose NS, Marcus A, Ballard H: Kaposi’s sarcoma in homosexual men-a report of eight cases. Lancet 1981, 2:598-600.
• [2]Curran JW, Jaffe HW: AIDS: the early years and CDC’s response. Morbidity and mortality weekly report. Surveillance summaries 2011, 60(4):64-69.
• [3]Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F: A review of human carcinogens–Part B: biological agents. Lancet Oncol 2009, 10:321-322.
• [4]Shiels MS, Pfeiffer RM, Gail MH, Hall HI, Li J, Chaturvedi AK: Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst 2011, 103:753-762.
• [5]Engels EA, Biggar RJ, Hall HI, Cross H, Crutchfield A, Finch JL: Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 2008, 123:187-194.
• [6]Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
• [7]Franceschi S, Lise M, Clifford GM, Rickenbach M, Levi F, Maspoli M: Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study. Br J Cancer 2010, 103:416-422.
• [8]Simard EP, Pfeiffer RM, Engels EA: Cumulative incidence of cancer among individuals with acquired immunodeficiency syndrome in the United States. Cancer 2011, 117:1089-1096.
• [9]Seaberg EC, Wiley D, Martinez-Maza O, Chmiel JS, Kingsley L, Tang Y: Cancer incidence in the multicenter AIDS Cohort Study before and during the HAART era: 1984 to 2007. Cancer 2010, 116:5507-5516.
• [10]Napravnik S, Eron JJ Jr, McKaig RG, Heine AD, Menezes P, Quinlivan E: Factors associated with fewer visits for HIV primary care at a tertiary care center in the Southeastern U.S. AIDS Care 2006, 18(1):S45-50.
• [11]Muggeo VM: Estimating regression models with unknown break-points. Stat Med 2003, 22:3055-3071.
• [12]Engels EA, Pfeiffer RM, Goedert JJ, Virgo P, McNeel TS, Scoppa SM: Trends in cancer risk among people with AIDS in the United States 1980–2002. AIDS 2006, 20:1645-1654.
• [13]Simard EP, Pfeiffer RM, Engels EA: Spectrum of Cancer Risk Late After AIDS Onset in the United States. Arch Intern Med 2010, 170:1337-1345.
• [14]Vishnu P, Aboulafia DM: AIDS-Related Non-Hodgkin’s Lymphoma in the Era of Highly Active Antiretroviral Therapy. Adv Hematol 2012, 2012:485943.
• [15]Krown SE, Lee JY, Dittmer DP: More on HIV-associated Kaposi’s sarcoma. N Engl J Med 2008, 358:535-536. author reply 536
• [16]Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S: Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006, 12:1365-1371.
• [17]Baum PD, Young JJ, Schmidt D, Zhang Q, Hoh R, Busch M: Blood T-cell receptor diversity decreases during the course of HIV infection, but the potential for a diverse repertoire persists. Blood 2012, 119:3469-3477.
• [18]Martin JN, Ganem DE, Osmond DH, Page-Shafer KA, Macrae D, Kedes DH: Sexual transmission and the natural history of human herpesvirus 8 infection. N Engl J Med 1998, 338:948-954.
• [19]Gao SJ, Kingsley L, Hoover DR, Spira TJ, Rinaldo CR, Saah A: Seroconversion to antibodies against Kaposi’s sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi’s sarcoma. N Engl J Med 1996, 335:233-241.
• [20]Silverberg MJ, Lau B, Justice AC, Engels E, Gill MJ, Goedert JJ: Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis 2012, 54:1026-1034.
• [21]Barta SK, Lee JY, Kaplan LD, Noy A, Sparano JA: Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphoma. Cancer 2012, 118:3977-3983.
• [22]Cianfrocca M, Lee S, Von Roenn J, Rudek MA, Dezube BJ, Krown SE: Pilot study evaluating the interaction between paclitaxel and protease inhibitors in patients with human immunodeficiency virus-associated Kaposi’s sarcoma: an Eastern Cooperative Oncology Group (ECOG) and AIDS Malignancy Consortium (AMC) trial. Cancer Chemother Pharmacol 2011, 68:827-833.
• [23]Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P: Antiretroviral Treatment of Adult HIV Infection: 2012 Recommendations of the International Anitviral Society-USA Panel. JAMA 2012, 308:387-402.
• [24]Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents: Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Edited by United States Department of Health and Human Services. Office of AIDS Research Advisory Council; 2012. http://www.aidsinfo.nih.gov/guidelines webcite
• [25]Howe CJ, Cole SR, Napravnik S, Eron JJ: Enrollment, retention, and visit attendance in the University of North Carolina Center for AIDS Research HIV clinical cohort, 2001–2007. AIDS Res Hum Retroviruses 2010, 26:875-881.
• [26]Fleming PL, Lansky A, Lee LM, Nakashima AK: The epidemiology of HIV/AIDS in women in the southern United States. Sex Transm Dis 2006, 33:S32-38.
• [27]Prejean J, Song R, Hernandez A, Ziebell R, Green T, Walker F: Estimated HIV incidence in the United States, 2006–2009. PLoS One 2011, 6:e17502.
• [28]Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC: Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009, 360:1815-1826.
• [29]When to Start Consortium: Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009, 373:1352-1363.